|Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase®|
RE Chandler, K Juhlin, J Fransson, O Caster, IR Edwards, GN Norén
Drug safety 40 (1), 81-90, 2017
|Vasculitis as an adverse event following immunization–systematic literature review|
C Bonetto, F Trotta, P Felicetti, GS Alarcón, C Santuccio, NS Bachtiar, ...
Vaccine 34 (51), 6641-6651, 2016
|Serious neurological adverse events after ivermectin—do they occur beyond the indication of onchocerciasis?|
The American journal of tropical medicine and hygiene 98 (2), 382-388, 2018
|Safety concerns reported by patients identified in a collaborative signal detection workshop using VigiBase: results and reflections from Lareb and Uppsala Monitoring Centre|
S Watson, RE Chandler, H Taavola, L Härmark, B Grundmark, A Zekarias, ...
Drug safety 41 (2), 203-212, 2018
|Transmission of Group A Streptococcus Limited to Healthcare Workers with Exposure in the Operating Room|
RE Chandler, LE Lee, JM Townes, RA Taplitz
Infection Control & Hospital Epidemiology 27 (11), 1159-1163, 2006
|Spontaneous reports of vasculitis as an adverse event following immunization: a descriptive analysis across three international databases|
P Felicetti, F Trotta, C Bonetto, C Santuccio, YB Pernus, D Burgner, ...
Vaccine 34 (51), 6634-6640, 2016
|Kawasaki disease and immunisation: A systematic review|
LK Phuong, C Bonetto, J Buttery, YB Pernus, R Chandler, P Felicetti, ...
Vaccine 35 (14), 1770-1779, 2017
|Safety concerns with HPV vaccines continue to linger: are current vaccine pharmacovigilance practices sufficient?|
Drug safety 40 (12), 1167-1170, 2017
|Optimizing safety surveillance for COVID-19 vaccines|
Nature Reviews Immunology 20 (8), 451-452, 2020
|Multisystem inflammatory syndrome in children and adults (MIS-C/A): Case definition & guidelines for data collection, analysis, and presentation of immunization safety data|
TP Vogel, KA Top, C Karatzios, DC Hilmers, LI Tapia, P Moceri, ...
|Modernising vaccine surveillance systems to improve detection of rare or poorly defined adverse events|
BMJ 365, 2019
|Data-driven identification of adverse event reporting patterns for Japan in VigiBase, the WHO global database of individual case safety reports|
R Wakao, H Taavola, L Sandberg, E Iwasa, S Soejima, R Chandler, ...
Drug safety 42 (12), 1487-1498, 2019
|Leveraging epidemiological principles to evaluate Sweden’s COVID-19 response|
S Baral, R Chandler, RG Prieto, S Gupta, S Mishra, M Kulldorff
Annals of epidemiology 54, 21-26, 2021
|Kawasaki disease and immunisation: standardised case definition & guidelines for data collection, analysis|
LK Phuong, C Bonetto, J Buttery, YB Pernus, R Chandler, KL Goldenthal, ...
Vaccine 34 (51), 6582-6596, 2016
|IgA vasculitis (Henoch-Schönlein): Case definition andguidelines for data collection, analysis, and presentation of immunisation safety data|
A Woerner, C Rudin, C Bonetto, C Santuccio, S Ozen, RP Wise, ...
Vaccine 35 (11), 1559-1566, 2017
|Risk factor considerations in statistical signal detection: using subgroup disproportionality to uncover risk groups for adverse drug reactions in VigiBase|
L Sandberg, H Taavola, Y Aoki, R Chandler, GN Norén
Drug safety 43 (10), 999-1009, 2020
|The role of pharmacovigilance and ISoP during the global COVID-19 pandemic|
RE Chandler, D McCarthy, JC Delumeau, M Harrison-Woolrych
Drug safety 43, 511-512, 2020
|Interstitial lung disease as an adverse drug reaction in Japan: exploration of regulatory actions as a basis for high reporting|
E Iwasa, Y Fujiyoshi, Y Kubota, R Kimura, RE Chandler, H Taavola, ...
Drug safety 43 (11), 1121-1131, 2020
|Nintedanib and ischemic colitis: Signal assessment with the integrated use of two types of real‐world evidence, spontaneous reports of suspected adverse drug reactions, and …|
Pharmacoepidemiology and drug safety 29 (8), 951-957, 2020
|Comment on “Safety of human papillomavirus vaccines: an updated review”|
RE Chandler, IR Edwards, M Lindquist
Drug safety 41 (5), 537-538, 2018